HomeScreenerEDITProfile
C
62/100

Editas Medicine

EDITGene Editing
📋
Analyst Summary
✓ VERIFIED2026-04-11

Editas Medicine (EDIT) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 2[1], 2 Phase 1[2].

EDIT has 3 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11)
  2. ClinicalTrials.gov (2026-04-11)
  3. ClinicalTrials.gov (2026-04-11)
  4. SEC EDGAR · 0001650664 (2026-04-11)
🏛
Upcoming Catalysts
EDIT-301 — sickle cell disease
2026-10-22
in 140d
🔬
Clinical Trials
3
NCT04853576Sickle Cell Disease, Hemoglobinopathies
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05444894Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06363760Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
3 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates1
Insider Filings1
Clinical Trials1
Data Provenance
cik1 verified
clinical trial3 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR